Mayer Timothy 4

What Happened
Timothy Mayer, Chief Operating Officer of NextCure, Inc. (NXTC), received a grant/award of 14,670 derivative shares (reported as acquisition code "A") on January 30, 2026. The filing reports $0.00 as the price/value on the Form 4; this reflects the award/option nature of the grant rather than a cash purchase or sale.

Key Details

• Transaction date: January 30, 2026; Form 4 filed February 3, 2026 (filed within the required two business days).
• Award: 14,670 derivative shares reported as acquired at $0.00.
• Shares owned after transaction: not specified in the filing.
• Vesting (per footnote): 25% vests on January 30, 2027; the remaining 75% vests in 36 equal monthly installments beginning February 28, 2027 (a four-year total vesting period).
• Transaction code: A = Award/Grant (derivative security). No 10b5-1 plan, tax withholding, or late filing was indicated.

Context
This was an equity award (not an open-market purchase or sale). For retail investors, awards are common for executive compensation and indicate future potential equity dilution as the award vests — they do not by themselves signal immediate buying or selling of stock.